The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
Parkinson's disease
Open accessAbstract
Parkinson's disease is a recognisable clinical syndrome with a range of causes and clinical presentations. Parkinson's disease represents a fast-growing neurodegenerative condition; the rising prevalence worldwide resembles the many characteristics typically observed during a pandemic, except for an infectious cause. In most populations, 3-5% of Parkinson's disease is explained by genetic causes linked to known Parkinson's disease genes, thus representing monogenic Parkinson's disease, whereas 90 genetic risk variants collectively explain 16-36% of the heritable risk of non-monogenic Parkinson's disease. Additional causal associations include having a relative with Parkinson's disease or tremor, constipation, and being a non-smoker, each at least doubling the risk of Parkinson's disease. The diagnosis is clinically based; ancillary testing is reserved for people with an atypical presentation. Current criteria define Parkinson's disease as the presence of bradykinesia combined with either rest tremor, rigidity, or both. However, the clinical presentation is multifaceted and includes many non-motor symptoms. Prognostic counselling is guided by awareness of disease subtypes. Clinically manifest Parkinson's disease is preceded by a potentially long prodromal period. Presently, establishment of prodromal symptoms has no clinical implications other than symptom suppression, although recognition of prodromal parkinsonism will probably have consequences when disease-modifying treatments become available. Treatment goals vary from person to person, emphasising the need for personalised management. There is no reason to postpone symptomatic treatment in people developing disability due to Parkinson's disease. Levodopa is the most common medication used as first-line therapy. Optimal management should start at diagnosis and requires a multidisciplinary team approach, including a growing repertoire of non-pharmacological interventions. At present, no therapy can slow down or arrest the progression of Parkinson's disease, but informed by new insights in genetic causes and mechanisms of neuronal death, several promising strategies are being tested for disease-modifying potential. With the perspective of people with Parkinson's disease as a so-called red thread throughout this Seminar, we will show how personalised management of Parkinson's disease can be optimised.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Strikingly, non-motor symptoms remain poorly responsive to current PD treatments despite being present from early prodromal PD and contributing significantly to overall disease burden [36].”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical practice guidelines support resilience training and exercise for patients with Parkinson’s disease (PD).”
From A randomized clinical trial of mindfulness meditation versus exercise in Parkinson’s disease during social unrest (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The diseases encompass various severe conditions, including neurodegenerative disorders like Alzheimer’s disease (AD) [3, 4] and Parkinson’s disease (PD) [5, 6], as well as traumatic brain injuries (TBI) [7] and spinal cord injuries (SCI) [8].”
From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Parkin and PINK1 mitigate STING-induced inflammation
Sliter, D. A., Martinez, J., Hao, L., Chen, X., Sun, N., Fischer, T. D., Burman, J. L., Li, Y., Zhang, Z., Narendra, D. P., et al. (2018) · Nature · doi:10.1038/s41586-018-0448-9 · Cited by 1,287
Self-citationRetractedStaging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653
Self-citationKalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Feigin, V. L., Nichols, E., Alam, T., Bannick, M. S., Beghi, E., Blake, N., Culpepper, W. J., Dorsey, E. R., Elbaz, A., Ellenbogen, R. G., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30499-x · Cited by 5,644
Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.018 · Cited by 3,622
Huber, M., Knottnerus, J. A., Green, L., van der Horst, H. E., Jadad, A. R., Kromhout, D., Leonard, B. E., Lorig, K. R., Loureiro, I., Meer, J. W. M. V. D., et al. (2011) · BMJ · doi:10.1136/bmj.d4163 · Cited by 2,983
Diagnosis and Treatment of Parkinson Disease: A Review
Armstrong, M. J., & Okun, M. S. (2020) · JAMA · doi:10.1001/jama.2019.22360 · Cited by 2,924
Self-citationDorsey, E. R., Elbaz, A., Nichols, E., Abbasi, N., Abd-Allah, F., Abdelalim, A., Adsuar, J. C., Ansha, M. G., Brayne, C., Choi, J.-Y. J., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30295-3 · Cited by 2,816
Nalls, M. A., Blauwendraat, C., Vallerga, C. L., Heilbron, K., Bandres-Ciga, S., Chang, D., Tan, M., Kia, D. A., Noyce, A. J., Xue, A., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30320-5 · Cited by 2,454
Cited by
Sorted by citations
Items 701–800 of 1,004
Yang, K., Lv, Z., Wen, Z., Lai, G., Zheng, C., Qi, F., Zhao, C., Hu, K., Chen, X., Fu, F., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1468850 · Cited by 19
ROS Regulation in CNS Disorder Therapy: Unveiling the Dual Roles of Nanomedicine
Quan, Z., Wang, S., Xie, H., Zhang, J., Duan, R., Li, M., & Zhang, J. (2024) · Small · doi:10.1002/smll.202410031 · Cited by 18
He, R. X., You, Z., Zhou, Y., Chen, G., Diao, Y., Jiang, X., Ning, Y., Zhao, G., & Liu, Y. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1520831 · Cited by 18
The Role of the Gastrointestinal Microbiota in Parkinson’s Disease
Gabrielli, M., Verme, L. Z. D., Zocco, M. A., Nista, E. C., Ojetti, V., & Gasbarrini, A. (2024) · Biomolecules · doi:10.3390/biom15010026 · Cited by 19
Solana‐Manrique, C., Sánchez‐Pérez, A. M., Paricio, N., & Muñoz‐Descalzo, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020620 · Cited by 21
DNA repair and disease: insights from the human DNA glycosylase NEIL family
Hwang, Y., Kang, S.-J., Kang, J., Choi, J., Kim, S.-J., & Jang, S. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01417-0 · Cited by 18
Chen, T., Xu, J., Tai, C., Wen, T., & Hsu, S. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123268 · Cited by 19
Ghanizada, H., & Nedergaard, M. (2025) · Handbook of clinical neurology · doi:10.1016/b978-0-443-19104-6.00006-1 · Cited by 22
Advances in biosensors for diagnosis of Alzheimer's and Parkinson's diseases
Negahdary, M., Sakthinathan, I., Mirsadoughi, E., Ligler, F. S., Coté, G. L., Forster, R. J., & Mabbott, S. B. (2025) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2025.117535 · Cited by 19
Generation of Neural Organoids and Their Application in Disease Modeling and Regenerative Medicine
Huang, R., Gao, F., Yu, L., Chen, H., & Zhu, R. (2025) · Advanced Science · doi:10.1002/advs.202501198 · Cited by 20
The Pharmaceutical Potential of α- and β-Amyrins
Viet, T. D., Anh, L. H., Xuan, T. D., & Dong, N. D. (2025) · Nutraceuticals · doi:10.3390/nutraceuticals5030021 · Cited by 23
Bao, Y., Miao, G., He, N., Bao, X., Shi, Z., Hu, C., Liu, X., Wang, B., & Sun, C. (2026) · Biology · doi:10.3390/biology15020189 · Cited by 18
Vuletić, V., Rački, V., Papić, E., & Peterlin, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137213 · Cited by 21
Compendium of causative genes and their encoded proteins for common monogenic disorders
Apgar, T. L., & Sanders, C. R. (2021) · Protein Science · doi:10.1002/pro.4183 · Cited by 21
Xu, X. H., Zeng, Z., Qi, Y., Ren, K., Zhang, C., Sun, B., & Li, D. (2021) · Neurosurgical FOCUS · doi:10.3171/2021.8.focus21383 · Cited by 18
Parkin as a Molecular Bridge Linking Alzheimer’s and Parkinson’s Diseases?
Checler, F., & da Costa, C. A. (2022) · Biomolecules · doi:10.3390/biom12040559 · Cited by 19
Khwaounjoo, P., Singh, G., Grenfell, S., Özsoy, B., MacAskill, M. R., Anderson, T., & Çakmak, Y. Ö. (2022) · Sensors · doi:10.3390/s22124613 · Cited by 18
Folkerts, A., Haarmann, L., Nielsen, J., Saliger, J., Eschweiler, M., Karbe, H., Allert, N., Vida, V., Trenkwalder, C., Kruse, A., et al. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-223314 · Cited by 20
Association of GBA genotype with motor and cognitive decline in Chinese Parkinson’s disease patients
Ren, J., Zhou, G., Wang, Y., Zhang, R., Guo, Z., Zhou, H., Zheng, H., Sun, Y. M., Ma, C., Lu, M., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1091919 · Cited by 18
Clinical trials for cognition in Parkinson's disease: Where are we and how can we do better?
Bayram, E., Batzu, L., Tilley, B. S., Gandhi, R., Jagota, P., Biundo, R., Garon, M., Prasertpan, T., Lazcano‐Ocampo, C., Chaudhuri, К. R., et al. (2023) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2023.105385 · Cited by 18
Rueda, M. P. C., Zanon, A., Gilmozzi, V., Lavdas, A. Α., Raftopoulou, A., Delcambre, S., Fabiola Del Greco, M., Klein, C., Grünewald, A., Pramstaller, P. P., et al. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00499-9 · Cited by 21
Self-citationEltoprazine modulated gamma oscillations on ameliorating L‐dopa‐induced dyskinesia in rats
Bi, Y.-W., Wang, P., Yu, J., Wang, Z., Yang, H., Deng, Y., Guan, J., & Zhang, W. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14241 · Cited by 18
Wang, W., Wang, Y., Wagner, K. M., Lee, R. D., Hwang, S. H., Morisseau, C. H. P., Wulff, H., & Hammock, B. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129938 · Cited by 19
Hong, C., Chung, C., Yu, R., & Chan, L. (2023) · eLife · doi:10.7554/elife.87501 · Cited by 18
van den Bergh, R., Evers, L. J. W., de Vries, N. M., de Lima, A. L. S., Bloem, B. R., Valenti, G., & Meinders, M. J. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1251395 · Cited by 18
Self-citationPradhan, S. H., Liu, J. Y., & Sayes, C. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216129 · Cited by 18
The gastrointestinal tract and Parkinson’s disease
Higinbotham, A. S., & Kilbane, C. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1158986 · Cited by 22
Action Observation and Motor Imagery as a Treatment in Patients with Parkinson’s Disease
Mezzarobba, S., Bonassi, G., Avanzino, L., & Pelosin, E. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-230219 · Cited by 18
Electrospun biosensors for biomarker detection
Zhou, J., Zheng, J., Wang, C., Zhang, G., Yang, H., Xiong, F., Fan, M., Wang, Z., Li, Y., & Yang, C. (2024) · Colloids and Interface Science Communications · doi:10.1016/j.colcom.2024.100767 · Cited by 18
Guo, X., Yu, J., Wang, R., Peng, N., & Li, R. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01424-9 · Cited by 21
Optogenetic and chemogenetic approaches for modeling neurological disorders in vivo
Krut’, V. G., Kalinichenko, A. L., Maltsev, D. I., Jappy, D., Shevchenko, E. K., Podgorny, O. V., & Belousov, V. V. (2024) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2024.102600 · Cited by 18
If Art Were a Drug: Implications for Parkinson’s Disease
Gros, P., Spee, B. T. M., Bloem, B. R., & Kalia, L. V. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-240031 · Cited by 18
Self-citationWang, Y., Ding, Y., & Guo, C. (2024) · Scientific Reports · doi:10.1038/s41598-024-64196-0 · Cited by 18
Missiego-Beltrán, J., Olalla-Álvarez, E. M., González-Brugera, A., & Beltrán-Velasco, A. I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168998 · Cited by 19
Meinhold, L., Gennari, A. G., Baumann‐Vogel, H., Werth, E., Schreiner, S. J., Ineichen, C., Baumann, C. R., & Tuura, R. (2024) · SLEEP · doi:10.1093/sleep/zsae233 · Cited by 21
Wallings, R. L., McFarland, K. N., Staley, H. A., Neighbarger, N. K., Schaake, S., Brüggemann, N., Zittel, S., Usnich, T., Klein, C., Sammler, E. M., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adl1535 · Cited by 19
Self-citationWang, J., Yuan, Y., Xie, T., Zhang, L., Xu, H., Lin, S.-C., Yang, Y., Zhu, D., & Zhuang, J. (2025) · Journal of science and medicine in sport · doi:10.1016/j.jsams.2025.01.003 · Cited by 19
Quan, P., Wang, K., Shi, Y., Wen, S., Wei, C., Zhang, X., Cao, J., & Yao, L. (2021) · Scientific Reports · doi:10.1038/s41598-021-92701-2 · Cited by 18
TREM2 in neurodegeneration and diseases
Abdulkhaliq, A. A., Alasiri, G., Kim, B., Khan, J., Ajoolabady, A., Yousof, S. M., Ren, J., Tuomilehto, J., Borai, A., Alrfaei, B. M., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03505-7 · Cited by 16
Wyse, R. K. H., Isaacs, T., Barker, R. A., Cookson, M., Dawson, T. M., Devos, D., Dexter, D. T., Duffen, J., Federoff, H. J., Fiske, B. K., et al. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-230363 · Cited by 19
Guo, X., Qiao, X., Li, X., Zhou, W., Liu, C., Yu, F., Chen, Q., Pan, M., Niu, X., Wang, L., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156547 · Cited by 20
A single-cell atlas to map sex-specific gene-expression changes in blood upon neurodegeneration
Grandke, F., Fehlmann, T., Kern, F., Gate, D., Wolff, T. W., Leventhal, O., Channappa, D., Hirsch, P., Wilson, E. N., Meese, E. U., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56833-7 · Cited by 20
Han, C., Wang, H., Zhang, M., Wu, L., Wang, A., Yang, P., Gao, Y., Zhang, C., Gao, J., Xue, T., et al. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03517-0 · Cited by 20
Cathepsins in Neurological Diseases
Lewandowski, D., Konieczny, M., Różycka, A., Chrzanowski, K., Owecki, W., Kalinowski, J., Stepura, M., Jagodziński, P. P., & Dorszewska, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167886 · Cited by 17
Distinct cutaneous α-synuclein signatures in body-first and brain-first Parkinson’s disease subtypes
Liu, M., Wen, T., Luo, H., Yang, T., Kong, Y., Jin, Y., Li, L., Yuan, Y., Liu, X., Yuan, J., et al. (2025) · Brain · doi:10.1093/brain/awaf395 · Cited by 18
Shang, H. F., Wang, Z., Sun, Y., Zuo, C., Wang, M., Zheng, K., Wang, Y., & Zhu, J. F. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05499-9 · Cited by 17
Mitochondrial DNA: a molecular switch driving sterile neuroinflammation
Jauhari, A., Singh, T., Carlisle, D. L., & Friedlander, R. M. (2026) · Translational Neurodegeneration · doi:10.1186/s40035-026-00540-w · Cited by 20
Santos‐García, D., Fonticoba, T. D. D., Bartolomé, C. C., Canfield, H., González, J. M. P., Miró, C. M., Aymerich, L. V., Suárez, E., Jesús, S., Aguilar, M., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11070626 · Cited by 17
What Do We Know about Theory of Mind Impairment in Parkinson’s Disease?
Trompeta, C., Rodríguez, B. F., & Gasca‐Salas, C. (2021) · Behavioral Sciences · doi:10.3390/bs11100130 · Cited by 17
Oikonomou, P., & Jost, W. H. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02529-x · Cited by 17
Guo, L., Qu, B., Song, C., Zhu, S., Gong, N., & Sun, J. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.08.026 · Cited by 17
Erythrocytic alpha-synuclein in early Parkinson's disease: A 3-year longitudinal study
Liu, G., Yu, Z., Gao, L., Zheng, Y., & Feng, T. (2022) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2022.09.011 · Cited by 17
Iron Overload Causes Ferroptosis But Not Apoptosis in MO3.13 Oligodendrocytes
Li, Y., Wang, B., Yang, J., Liu, R., Xie, J., & Wang, J. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03807-6 · Cited by 17
Wang, H., Hao, X., Ren, L., Li, T., Pu, L., Liu, W., & Liang, Z. (2022) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2022.11.012 · Cited by 17
Potential Benefits of Anthocyanins in Chronic Disorders of the Central Nervous System
Panchal, S. K., & Brown, L. (2022) · Molecules · doi:10.3390/molecules28010080 · Cited by 18
Gene Expression Profiling as a Novel Diagnostic Tool for Neurodegenerative Disorders
Martínez-Iglesias, O. A., Naidoo, V., Carril, J. C., Seoane, S., Cacabelos, N., & Cacabelos, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065746 · Cited by 18
The effects of AQP4 rs162009 on resting‐state brain activity in Parkinson's disease
Jiang, M., Fang, Y., Dai, S., Si, X., Wang, Z., Tang, J., Gao, T., Liu, Y., Song, Z., Pu, J., et al. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14208 · Cited by 15
Sun, Y., Zhou, X., Liang, X., Lin, J., Xu, Y., Chen, C., Wei, S., Chen, Q.-S., Liu, F., Zhao, J., et al. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00518-9 · Cited by 19
GV ‐971 attenuates α‐Synuclein aggregation and related pathology
Yu, Z., Yang, Y., Chan, R., Shi, M. Y., Stewart, T., Huang, Y. Z., Liu, Z., Lan, G., Sheng, L., Tian, C., et al. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14393 · Cited by 17
EEF1A1 is Involved the Regulating Neuroinflammatory Processes in Parkinson's Disease
Aisha, Z., Lei, J., Zhang, Y., & Ma, J. (2023) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2205122 · Cited by 17
Zailani, H., Satyanarayanan, S. K., Liao, W.-C., Hsu, Y., Huang, S., Gałecki, P., Su, K., & Chang, J. P. (2023) · Nutrients · doi:10.3390/nu15204363 · Cited by 17
Chiral discrimination of l -DOPA via l / d -tryptophan decorated carbon quantum dots
Rezaei, A., Hamad, M. A., Adibi, H., Zheng, H., & Qadir, K. H. (2024) · Materials Advances · doi:10.1039/d3ma00757j · Cited by 17
Beura, S. K., Panigrahi, A. R., Yadav, P., Palacio, I., Casero, E., Quintana, C., Singh, J., Singh, S. K., Martín-Gago, J. Á., & Singh, S. K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102205 · Cited by 17
Levodopa Impairs the Energy Metabolism of the Basal Ganglia In Vivo
Prasuhn, J., Schiefen, T., Güber, T., Henkel, J., Uter, J. C., Steinhardt, J., Wilms, B., & Brüggemann, N. (2024) · Annals of Neurology · doi:10.1002/ana.26884 · Cited by 17
Epigenetics and the neurodegenerative process
Słowikowski, B. K., Owecki, W., Jeske, J., Jezierski, M., Draguła, M., Goutor, U., Jagodziński, P. P., Kozubski, W. P., & Dorszewska, J. (2024) · Epigenomics · doi:10.2217/epi-2023-0416 · Cited by 17
Wang, Y., Xiao, Y., Xing, Y., Yu, M., Wang, X., Ren, J., Liu, W., & Zhong, Y. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14680 · Cited by 16
Meng, D., Wu, J., Huang, X., Liang, X., & Fang, B. (2024) · BMC Public Health · doi:10.1186/s12889-024-18653-0 · Cited by 17
Zhang, C., Zhou, J., Zhuo, L., Zhang, W., Lv, L., Zhu, L., Zhang, J., Feng, F., Liu, W., Han, L., et al. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118391 · Cited by 18
Li, L., Zhang, Y., Chen, Z., Xu, C., Xu, Z., Pei, H., Wang, W., Yao, R., & Hao, C. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176743 · Cited by 18
Comprehensive analysis of adverse events associated with pimavanserin using the FAERS database
Gu, J., Qu, Y., Shen, Y., Zhou, Q., Jiang, Y., & Zhu, H. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.07.103 · Cited by 17
Zeng, Y., Lin, J., Li, Z., Xiao, Z., Wang, C., Ge, X., Wang, C., Huang, G. C., & Liu, M. (2024) · NeuroImage · doi:10.1016/j.neuroimage.2024.120750 · Cited by 17
Zhao, R. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00428-7 · Cited by 17
Xu, Y., Su, Y. A., Cai, S., Yao, Y., & Chen, X. (2024) · Public Health · doi:10.1016/j.puhe.2024.10.035 · Cited by 17
The emerging role of oxygen redox in pathological progression of disorders
Li, S.-Y., Gong, X., Ndikuryayo, F., & Yang, W. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102660 · Cited by 17
Zhang, G., Ma, C., Ma, L., Wei, D., Wu, Y., Li, Y., Xu, Z. H., Liu, Y., Cai, Y., Yu, E. Y.-W., et al. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.4c04269 · Cited by 17
Haploinsufficiency of ITSN1 is associated with a substantial increased risk of Parkinson’s disease
Spargo, T. P., Sands, C. F., Juan, I. R., Mitchell, J., Ravanmehr, V., Butts, J. C., De-Paula, R. B., Kim, Y., Hu, F., Wang, Q., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115355 · Cited by 17
Significance of nicotine and nicotinic acetylcholine receptors in Parkinson’s disease
Xia, L., Li, Q., Pu, M., Dong, H., & Zhang, Q. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1535310 · Cited by 20
The etiopathogenetic and pathophysiological spectrum of parkinsonism
Bologna, M., Truong, D. D., & Jankovic, J. J. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120012 · Cited by 18
Botulinum toxin for the treatment of tremor
Mittal, S. O., & Pandey, S. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120203 · Cited by 19
Including People with Parkinson’s Disease in Clinical Study Design and Execution: A Call to Action
Meinders, M. J., Donnelly, A. C., Sheehan, M., & Bloem, B. R. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-223190 · Cited by 17
Self-citationLiao, Z., Gong, Z., Wang, Z., Yang, W., Liu, W., Hou, L., Liu, X., Hua, J., Wang, B., & Li, N. (2022) · Cells · doi:10.3390/cells11172706 · Cited by 17
Cui, J., Wang, W., Tang, Y., Feng, S., Liu, H., & Hao, Z. (2025) · Interdisciplinary medicine · doi:10.1002/inmd.20240041 · Cited by 21
Carrillo, F., Ghirimoldi, M., Fortunato, G., Palomba, N. P., Ianiro, L., Giorgis, V. D., Khoso, S., Giloni, T., Pietracupa, S., Modugno, N., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-024-00853-5 · Cited by 16
Li, H., Dong, K., Zhao, M., Li, R., Shi, C., Wang, C., Wei, Y., Li, J., Chen, L., Zhao, Y., et al. (2025) · Environmental Science & Technology · doi:10.1021/acs.est.5c02319 · Cited by 16
Li, Z., Miao, X., Zhang, Q., Shen, J., Jia, Y., Ge, S., Ji, P., Wang, J., Zhang, K., & Wang, M. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01074-0 · Cited by 18
Song, B., Niu, W., Sun, H., Hao, M., Xie, R., Lv, J., Tong, C., & Jin, C. (2025) · Fitoterapia · doi:10.1016/j.fitote.2025.106766 · Cited by 17
Human Glucose Transporters in Health and Selected Neurodegenerative Diseases
Szablewski, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157392 · Cited by 18
Sleep Disorders in Neurodegenerative Diseases with Dementia: A Comprehensive Review
Siwecka, N., Golberg, M., Świerczewska, D., Filipek, B., Pendrasik, K., Bączek-Grzegorzewska, A., Stasiołek, M., & Matysiak, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14197119 · Cited by 19
Wang, H., Xu, J., Yu, M., Ma, X., Li, Y., Pan, C., Ren, J., & Liu, W. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.03.032 · Cited by 16
High rates of blood transfusion associated with Parkinson’s disease
Shahrestani, S., Gendreau, J. L., Tafreshi, A. R., Brown, N. J., & Dashtipour, K. (2022) · Neurological Sciences · doi:10.1007/s10072-022-06097-6 · Cited by 17
Domingos, J., Dean, J., Fernandes, J. B., & Godinho, C. (2022) · JMIR Aging · doi:10.2196/40325 · Cited by 16
Lenka, A., & Jankovic, J. J. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2177535 · Cited by 16
Association of women-specific health factors in the severity of Parkinson’s disease
Rao, S. C., Li, Y., Lapin, B. R., Pattipati, S., Galvelis, K. G., Naito, A., Gutierrez, N., Leal, T. P., Salim, A., Salles, P. A., et al. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00524-x · Cited by 16
Robust and language-independent acoustic features in Parkinson's disease
Scimeca, S., Amato, F., Olmo, G., Asci, F., Suppa, A., Costantini, G., & Saggio, G. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1198058 · Cited by 16
Identification of Cuproptosis Clusters and Integrative Analyses in Parkinson’s Disease
Zhang, M., Meng, W., Liu, C., Wang, H., Li, R., Wang, Q., Gao, Y., Zhou, S., Du, T., Yuan, T., et al. (2023) · Brain Sciences · doi:10.3390/brainsci13071015 · Cited by 16
Wang, P., Chen, Q., Tang, Z., Wang, L., Gong, B., Li, M., Li, S., & Yang, M. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1231707 · Cited by 16
Contini, C., Fadda, L., Lai, G., Masala, C., Olianas, A., Castagnola, M., Messana, I., Iavarone, F., Bizzarro, A., Masullo, C., et al. (2023) · PROTEOMICS · doi:10.1002/pmic.202300202 · Cited by 16
A review of emergent intelligent systems for the detection of Parkinson’s disease
Dhanalakshmi, S., Maanasaa, R. S., Maalikaa, R. S., & Senthil, R. (2023) · Biomedical Engineering Letters · doi:10.1007/s13534-023-00319-2 · Cited by 16
Cao, Q., Han, X., Tang, D., Qian, H., Yan, K., Shi, X., Li, Y., & Zhang, J. (2023) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-23-87 · Cited by 16
Meng, L., Wang, D., Shi, Y., Li, Z., Zhang, J., Lu, H., Zhu, X., & Ming, D. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1252610 · Cited by 16
Metadata
- Authors
- Bloem, B. R., Okun, M. S., & Klein, C.
- Affiliations
- Radboud University Nijmegen (NL)
- University of Florida Health (US)
- University Hospital Schleswig-Holstein (DE)
- Corresponding author
- Bloem, Bastiaan R
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2021-06
- Volume
- 397
- Issue
- 10291
- Pages
- 2284-2303
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4206481149
- Cited by
- 3,920
- References
- 159
- Citations by year
- 2026: 878 · 2025: 1098 · 2024: 901 · 2023: 607 · 2022: 364 · 2021: 72
- FWCI
- 62.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- Deutsche Forschungsgemeinschaft
- Parkinson's Foundation (FOR2488)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, neurodegeneration, genetic risk variants, monogenic Parkinson's disease, non-motor symptoms, levodopa, disease-modifying therapy, multidisciplinary care, non-pharmacological treatment, diagnosis, prodromal period
- MeSH terms
- Antiparkinson Agents, Humans, Levodopa, Parkinson Disease, Time Factors, Tremor, Disease Management, Prodromal Symptoms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
